3Vote!
10Q Detective (Free subscription) | yesterday
Novartis AG (NVS-$55.85) loses patent protection for its $4.4 billion blood pressure medicine Diovan (valsartan) in the major countries of the European Union in 2011 and the following September here in the U.S. Expect generic challengers to strangle Exforge’s (valsartan-amlodipine) lease-on-life, too. Does anyone know CPR? The drugmaker is reaching into its life-cycle playbook to introduce
+Vote!
Seattle Times (Free subscription) | yesterday
Idera Pharmaceuticals Inc. on Wednesday announced the end of a research partnership with Novartis AG, but said Merck & Co. is extending its work with Idera for another year.
+Vote!
San Fransisco Chronicle (Free subscription) | yesterday
Idera Pharmaceuticals Inc. on Wednesday announced the end of a research partnership with Novartis AG, but said Merck & Co. is extending its work with Idera for another year. Novartis, a Swiss drugmaker, will end its work with Idera on Feb. 21, 2010. The... Merck & Co - Novartis - Switzerland - Idera Pharmaceuticals - Business
+Vote!
San Diego Union (Free subscription) | yesterday
Idera Pharmaceuticals Inc. on Wednesday announced the end of a research partnership with Novartis AG, but said Merck & Co. is extending its work with Idera for another year.
+Vote!
Seattle Post-Intelligencer (Free subscription) | yesterday
NEW YORK -- Idera Pharmaceuticals Inc. on Wednesday announced the end of a research partnership with Novartis AG, but said Merck & Co. is extending its work with Idera for another year.
4Vote!
Market Watch (Free subscription) | yesterday
BOSTON (MarketWatch) -- Drug stocks edged higher in early trading Wednesday as shares of Incyte Corp. jumped on news that it has signed a drug development pact with Novartis AG worth up to $1.1 billion, plus royalties on future sales. The NYSE Arca Pharmaceutical Index climbed 0.5% to 309.20 as the NYSE Arca Biotechnology Index rose marginally to 891.08. Shares of Incyte were up 8% at $8.31. Market...
4Vote!
Market Watch (Free subscription) | yesterday
BOSTON (MarketWatch) -- Idera Pharmaceuticals said early Wednesday that Novartis AG plans to terminate the companies' collaboration agreement on Feb. 21, 2010. The pact focused on the development of potential treatments for asthma and allergies. As a result of the termination, Idera will regain the rights to the compound IMO-2134, which was in Phase I testing. Market Pulse Stories are Rapid-fire,...
5Vote!
The Triangle Business Journal (Free subscription) | 11/24/2009
The top brass of Swiss drug maker Novartis AG is expected to be in Holly Springs this afternoon at a ribbon-cutting ceremony for a $1.2 billion facility that will be the first in the United States to use a new cell-culture technology to produce flu vaccines. (NVS)
5Vote!
Chicago Tribune (Free subscription) | 11/24/2009
BASEL, Switzerland Swiss pharmaceuticals maker Novartis AG has opened the first U.S. plant to produce flu vaccines using cell cultures instead of egg-based methods, it said Tuesday.
4Vote!
Jim Cramer's Mad Money (Free subscription) | 11/24/2009
Jim Cramer’s Mad Money Stock Picks for Monday November 23 2009. These are all of Jim Cramer’s stock picks that are a Buy! I bold my picks. Buy: Stanley Works (SWK) Masco (MAS) Black & Decker (BDK) Home Depot (HD) Sanofi-Aventis (SNY) CIENA (CIEN) Whirlpool (WHR) Verizon (VZ) AT&T (T) Amazon.com (AMZN) Nordic American Tanker (NAT) Sell: Vimpel Communications (VIP) Novartis AG (NVS)...
Click here to see all comments
MAXIDEX DEXAMETHASONE WARNING
I had eye surgery and in the post-op pack was MAXIDEX(dexamethasone) drops by ALCON LABS.
Two days later I was BLIND
Use Google and enter EPOCRATES...
anonymous - 11/24/2009
4Vote!
Madd Money (Free subscription) | 11/24/2009
Bullish Verizon Communications (VZ), AT&T Inc. (T), Sanofi-Aventis SA (ADR)(NYSE:SNY) and CIENA Corp. (CIEN). Bearish Vimpel Communications (ADR)(NYSE:VIP) and Novartis AG (NVS). Join the fastest growing community of small cap investors at Stockhideout.com
Click here to see all comments
MAXIDEX DEXAMETHASONE WARNING
I had eye surgery and in the post-op pack was MAXIDEX(dexamethasone) drops by ALCON LABS.
Two days later I was BLIND
Use Google and enter EPOCRATES...
anonymous - 11/24/2009
4Vote!
Miami Herald (Free subscription) | 11/17/2009
Pharmaceutical maker Novartis AG said Tuesday a U.S. clinical study suggests that half a dose of its swine flu vaccine may be sufficient to protect people from the virus and could allow many more to be immunized with current supplies.
3Vote!
Health - The Post Chronicle (Free subscription) | 11/17/2009
A U.S. clinical study suggests that just half a dose of the Novartis AG H1N1 vaccine may be enough to generate a protective immune response, the Swiss drugmaker said on Tuesday....
7Vote!
Boston Globe (Free subscription) | 11/13/2009
Swiss pharmaceutical company Novartis AG said Friday it has received regulatory approval in Switzerland for a swine flu vaccine produced using cell cultures instead of egg-based methods.
4Vote!
Miami Herald (Free subscription) | 11/13/2009
Serbia's health authorities have ordered three million swine flu vaccines from Swiss pharmaceutical company Novartis AG worth an estimated euro24 million ($36 million).
3Vote!
obi jo | 07/27/2009
http://benkazie.wordpress.com/2009/07/27/quick-post-panel-urges-fda-to-expedite-swine-flu-vaccine-approval/ US Global health officials are scrambling to try to prevent the spread of the H1N1 swine flu virus, with US officials moving Thursday with a recommendation that the Food and Drug Administration approve or license a vaccine. A federal advisory panel said the FDA should move ahead to approve or
3Vote!
ravjen | 06/14/2009
Swine flu vaccine successfully produced weeks ahead of expectations of the Swiss pharmaceutical company Novartis AG . The vaccine was made in cells, rather than grown in eggs as is usually the case with vaccines.
Videos